Nanobiotix S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Nanobiotix S.A. for the month of September 2025. The filing, dated September 17, 2025, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release and does not contain embedded financial tables or statements.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The specific content of the referenced press release is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the attached Exhibit 99.1, which is not part of the input text.
Key Facts for Investor Verification
- Verify the full content of the press release dated September 17, 2025, referenced as Exhibit 99.1.
- Confirm the specific operational or clinical milestone announced in the press release, as the Form 6-K itself contains no substantive details.
- Review the registrant's principal executive office location in Paris, France.
- Note that the report was signed by Bart Van Rhijn, Chief Financial Officer.